Most Recent Peer-Reviewed Journal Publications

    Isonishi, S., Ohkawa, K., Tanaka, T., and Howell, S.B. Depletion of protein kinase C (PKC) by 12-O-tetradecanoyl-phorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells. Brit. J. Cancer, 82:34-38, 2000.

    De las Alas, M.M., Christen, R.D., Gately, D.P., Weiner, D.E., Benbatoul, K., Kirmani, S., D'Agostino, H.R., Plaxe, S.C., Darrah, D., McClay, E.F., Aebi, S., Howell, S.B., Los, G. Increase in tumor GADD153 mRNA level following treatment correlates with response to paclitaxel. Cancer Chemother. Pharmacol., 45:381-388, 2000.

    Fink, D., and Howell, S.B. How does cisplatin kill cells? in "Platinum-Based Drugs in Cancer Therapy", Humana Press, New Jersey, 149-167, 2000.

    Samimi, G., Fink, D., Varki, N.M., Husain, A., Hoskins, W.J., Alberts, D.S., and Howell, S.B. Analysis of MLH1 and MSH2 expression in ovarian cancer prior to and following platinum drug-based chemotherapy. Clin. Cancer Res., 6:1415-1421, 2000.

    Johnsson, A., Zeelenberg, I., Min, Y., Hilinski, J., Berry, C., Howell, S.B. and Los, G. Identification of genes differentially expressed in association with acquired cisplatin resistance.. Brit. J. Cancer, 83:1047-1054, 2000.

    Howell, S.B. Resistance to apoptosis in prostate cancer cells. Mol. Urology, 4:225-229, 2000.

    Lin, X., Ramamurthi, K., Mishima, M., Kondo, A., and Howell, S.B. p53 interacts with the DNA mismatch repair system to modulate the cytotoxicity and mutagenicity of hydrogen peroxide. Mol. Pharmacol., 58:1222-1229, 2000.

    Perego P, Jimenez G, Gatti L, Howell S and Zunino F. Yeast mutants as a model system for identification of determinants of chemosensitivity. Pharmacological Reviews, 52:477-491, 2000.

    Li, H., Jiang, X., Howell, S.B., and Goodman, M. Synthesis, Conformational anaylsis and bioactivity of Lan-7, a lanthionine of TT-232. J. Peptide Sci. 6:26-35, 2000.

    Robbins, K.T., Kumar, P., Wong, F.S.H., Hartsell, W.r., Flick, P., Palmer, R., Weir III, A.B., Neill, H.B., Murry, T., Ferguson, R., Hanchett, C., Vieira, F., Bush, A., Howell, S.B. Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head & Neck 22: 687-693, 2000.

    Jaeckle, K.A., Phuphanich, S., van den Bent, M.J., Aiken, R., Batchelor, T., Campbell, T., Fulton, D., Gilbert, M., Heros, D., Rogers, L., O'Day, S.J., Akerley, W., Allen J., Baidas, S., Gertler, S.Z., Greenberg, H.S., LaFollette, S., Lesser, G., Mason,W., Recht, L., Wong, E., Chamberlain,M.C., Cohn, A., Glantz, M.J., Gutheil, J.C., Maria, B., Moots, P., New, P., Russell, C., Shapiro, W., Swinnen, L., and Howell, S.B. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Brit. J. Cancer, 84:157-163, 2001.

    Lin, X., Gately, D.P., Hom, D., Mishima, M., Los, G., and Howell, S.B. Quantification of tumor cell injury in vitro and in vivo using expression of green fluorescent protein under the control of the GADD153 promoter. Int. J. Cancer, 91:555-562, 2001.

    Lin, X., Ramamurthi, K., Mishima, M., Kondo, A., Christen, R.D. and Howell, S.B. p53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res., 61:1508-1516, 2001.

    Bonetti, A., Zaninelli, M., Leone, R., Franceschi, T., Pasini, F., Cetto, G.L., Sich, D., Brienza, S., and Howell, S.B. Use of the ratio of time to progression following first and second line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma. Annals Oncol.., 12:187-91, 2001.

    Bergoglio, V., Canitrot, Y., Hogarth, L., Minto, L., Howell, S.B., Cazaux, C., Hoffmann, J-S. Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents. Oncogene, 20:6181-6187, 2001.

    Kondo, A., Safaei, R., Mishima, M., Lin, X., Niedner, H., and Howell, S.B. Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair. Cancer Res., 61:7603-7607, 2001.

    Howell, S.B. Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam technology. The Cancer Journal, 7:219-227, 2001.

    Niedner, H., Christen, R., Lin, X., Kondo, A., and Howell, S.B. Identification of genes that mediate sensitivity to cisplatin. Mol. Pharmacology, 60:1153-1160, 2001.

    Los, G, Yang, F., Samimi, G., Manorek, G., Guerorguieva, I.M., Howell, S., van Erp, N., Breaux, J.K. Using mRNA expression profiling to determine anticancer drug efficacy. Cytometry 47: 66-71, 2002.

    Mishima, M., Samimi, G., Kondo, A., Lin, X., and Howell, S.B. Cellular pharmacology of oxaliplatin resistance. Eur J Cancer, 38:1405 - 1412, 2002.

    Lin, Xinjian, Okuda, T., Holzer, A., Howell, S.B. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol, 62:1154-1159, 2002.

    Katano, K., Kondo, A., Safaei, R., Holzer, A., Samimi, G., Mishima, M., Kuo, Y.M., Rochdi, M., and Howell, S.B. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Research 62: 6559-6565, Nov. 15, 2002.

    Alberts, D., Markman, M., Armstrong, D., Rothenberg, M.L., Muggia, F., and Howell, Stephen B. Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J Clin Onco, 20 (19):3944-3946, 2002.

    De las Alas, M., Los, G., Lin, X., Kurdi-Haidar, B., Howell, S.B. Identification of transdomiant negative suppressor elements derived from hMSH2 that mediate resistance to 6-thioguanine. Mol Pharmacol, 2002 Nov; 62(5):1198-206

    Fedier A., Schlamminger M., Schwarz V.A., Haller U., Howell S.B., Fink D. Loss of atm sensitizes p53-deficient cells to topoisomerase poisons and antimetabolites. Annals Oncol, 14:938-945, 2003.

    Jaeckle, K.A., Batchelor, T., O'Day, S.J., Phuphanich, S., New, P., Lesser, G., Cohn, A., Gilbert, M., Aiken, R., Heros, D., Rogers, L., Wong, E., Fulton, D., Gutheil, J.C., Baidas, S., Kennedy, J.M., Mason,W., Moots, P., Russell, C., Swinnen, L., and Howell, S.B. An open-label trial of sustained-release cytarabine (DepoCytTM) for the Intrathecal treatment solid tumor neoplastic meningitis. J. Neuro-Oncol, 57: 231-239, 2002 , 2003.

    Cruz-Monserrate, Z.,Vervoort, H.C., Bai, R., Newman, D.J., Howell, S.B., Los, G., Mullaney, J.T., Williams, M.D., Pettit, G.R., Fenical, W., and Hamel, E. Diazonamide A and a synthetic structural analog: disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulin. Mol Pharmacol, 63:1273-1280, 2003.

    Samimi, G.,Varki, N.M., Wilczynski, S., Safaei, R., Alberts,D.S., and Howell, S.B. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin Cancer Res, 9:5853-5859, 2003.

    Katano, K., Safaei, R., Samimi, G., Holzer, A., Rochdi, M., and Howell, S.B.The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol Pharmacol, 64:466-473, 2003.

    Samimi, G.,Varki, N.M., Wilczynski, S., Safaei, R., Alberts,D.S., and Howell, S.B. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin Cancer Res, 9:5853-5859, 2003.

    Lin, X., Zhang, Q., Rice, J.R., Stewart , D.R., Nowotnik, D.P., and Howell, S.B. Improved Targeting of Platinum Chemotherapeutics: The anti-tumor activity of the HPMA copolymer platinum agent AP5280 in murine tumor models. Eur J Cancer, 40:291-297, 2004.

    Safaei, R., Katano, K., Samimi, G., Naerdemann, W., Stevenson, J.L., Rochdi, M. and Howell, S.B. Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemother Pharmacol, 53:239-46, 2004

    Rademaker-Lakhai, J,M., Terret, C., Howell, S.B., Baud, C.M., de Boer, R.F., Pluim, D. Beijnen, J.H., Schellens, J.H.M., J.P. Droz, J.P., A Phase I and pharmacologic study of the platinum polymer AP5280 given as an intravenous infusion once every three weeks in patients with solid tumors. Clin Cancer Res, 10:3386-95, 2004.

    Samimi, G., Katano, K., Holzer, A. K., Safaei, R., Howell, S.B., Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol Pharmacol, 66:25-32, 2004.

    Katano, K., Safaei, R., Samimi, G., Holzer, A., Tomioka, M., Goodman, M. and Howell, S.B . Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells. Clin Cancer Res, 10:4578-4588, 2004.

    Holzer, A.K., Samimi, G., Katano, K., Naerdemann, W., Lin, X., Safaei, R. and Howell, S.B. The copper influx transporter Human Copper Transport Protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol. 66:817-823, 2004.

    Samimi, G., Safaei, R., Katano, K., Holzer, A. K., Rochdi, M., Tomioka, M., Goodman, M., Howell, S.B., Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin and oxaliplatin in ovarian cancer cells. Clin Cancer Res, 10:4661-4669, 2004.

    Holzer, A.K., Katano, K., Klomp, L. W.J. and Howell, S.B. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in human ovarian carcinoma cells. Clin. Cancer Res, 10:6744-6749, 2004.

    Wu, F., Lin, X., Okuda, T., Howell, S.B. DNA Polymerase z regulates cisplatin cytotoxicity, mutagenicity and the rate of development of cisplatin resistance. Cancer Res, 64:8029-8035, 2004.

    Samimi, G., Manorek, G., Castel, R., Breaux,J.K., Cheng,T.C., Berry ,C.C., Los, G. and Howell,S.B. cDNA microarray-based identification of genes and mechanisms associated with oxaliplatin resistance. Cancer Chemother Pharmacol, 55:1-11, 2005.

    Safaei, R., Samimi, G., Holzer, A.K., Naerdemann, W., Tomioka, M., Goodman, M. and Howell, S.B. Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells. Clin Cancer Res, 11: 756-767, 2005.

    Safaei, R., Howell, S.B. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit. Rev. Hematology, 53: 13-23, 2005.

    Wilczynski, S.P., Chen,Y.Y., Chen, W.,Howell, S.B., Shively, J.E., Alberts D.S. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFR-alpha, PDGFR-beta in ovarian cancer. Human Pathol 36:242-249, 2005.

    Okuda, T., Lin, X., Trang, J., and Howell, S.B. Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin. Mol Pharmacol. 67:1852-1860, 2005.

    Samimi, G., Howell, S.B. Modulation of the cellular pharmacology of JM-118, the major metabolite of satraplatin, by copper influx and efflux transporters. Cancer Chem Pharm, 57:781-8,2006.

    Safaei, R., Larson, B.J., Cheng, T.C., Gibson, M.A., Otani, S., Naerdemann, W. and Howell, S.B. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther, Oct 4:1595-604, 2005.

    Lin, X., Trang, J., Okuda, T., Howell, S.B. DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair. Clin Cancer Res, 12:563-568, 2006.

    Lin, X. Okuda, T., Trang, J., and Howell, S.B. hREV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells. Mol Pharmacol 69:1748-1754, 2006

    Cheng, T.C., Manorek, G., Samimi, G., Lin, X., Berry, C.C., Howell, S.B. Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemo Pharm, 58:384-95, 2006

    Rice, J.R., Gerberich, J.L., Nowotnik, D.P., and Howell, S.B. Preclinical efficacy and pharmacokinetics of AP5346, a novel DACH-platinum tumor-targeting drug delivery system. Clin Cancer Res, 12:2248-2254, 2006.

    Lin, X., and Howell, S.B. DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Mol Cancer Therapeut, 5:1239-1247, 2006.

    Holzer, A.K., Varki, N.M., Le, Q.T., Naredi, P., Gibson, M.A., and Howell, S.B. Expression of the human copper influx transporter 1 in normal and malignant human tissues. J Histochem Cytochem, 54:1041-1049, 2006.

    Holzer, A.K., Manorek, G.H., Howell, S.B. The contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin and oxaliplatin. Mol Pharmacol, 70:1390-1394, 2006.

    Samimi, G., Kishimoto, S., Manorek, G., Breaux, J.K., and Howell, S.B. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin. Cancer Chemo Pharm, 59:301-312, 2007.

    Holzer, A.K. and Howell, S.B. The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res, 66:10944-10952, 2006.

    Kong , S.D. , Luong, A., Manorek, G., Howell, S.B., Yang, J. Acidic Hydrolysis of N -ethoxybenzylimidazoles (NEBIs): Potential Applications as pH-Sensitive Linkers for Drug Delivery. Bioconjug Chem, 18: 293-296, 2007.

    Campone, M., Rademaker-Lakhai, J.M., Bennouna, J., Howell, S.B., Nowotnik, D.P., Beijnen, J.H., Schellens, J.H.M. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every four weeks to advanced solid tumor patients. Cancer Chemother Pharmacol, Feb 17, 2007 [Epub ahead of print]